National Multiple Sclerosis Society
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1946-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Improving Hand Use in Multiple Sclerosis
Phase 2
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Multiple Sclerosis Society
- Target Recruit Count
- 66
- Registration Number
- NCT01081275
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2008-06-11
- Lead Sponsor
- National Multiple Sclerosis Society
- Target Recruit Count
- 7
- Registration Number
- NCT00695084
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
News
UAE Grants World's First Approval for Tolebrutinib, Breakthrough Oral Treatment for Progressive Multiple Sclerosis
The Emirates Drug Establishment has approved Tolebrutinib, making the UAE the first country to authorize this oral treatment for non-relapsing secondary progressive multiple sclerosis (SPMS).